Emergent BioSolutions Inc.
EBSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for EBS. That does not mean none is planned.
Get an email about EBS's next catalysts
Track Emergent BioSolutions (EBS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
WebsiteACAM2000
Smallpox Vaccine Adverse Reaction
CHIKV VLP/adjuvant
Chikungunya Virus
BioThrax
Anthrax
HuMax-CD4
T Cell Lymphoma
AV7909
Anthrax
PXVX0200
Cholera
Raxibacumab
Therapeutic Treatment of Inhalation Anthrax
Gamunex
Anthrax
PXVX0200 10E9
Cholera
of 1.7 x 10^10 CFU (Cohort 4)
Typhoid
1.1 x 10^10 CFU (Cohort 3)
Typhoid
5.0 x 10^9 CFU (Cohort 1)
Typhoid
7.5 x 10^9 CFU (Cohort 2)
Typhoid
FLU-IGIV
Influenza A H3N2
Vaccinia virus: ACAM2000 smallpox vaccine
Smallpox
ACAM2000 Smallpox Vaccine
Smallpox
AIGIV
Anthrax
Ciprofloxacin
Anthrax
PXVX0200 10E8
Cholera
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACAM2000 | Phase 3 | Smallpox Vaccine Adverse Reaction | - | - |
CHIKV VLP/adjuvant | Phase 3 | Chikungunya Virus | - | - |
BioThrax | Phase 3 | Anthrax | - | - |
HuMax-CD4 | Phase 3 | T Cell Lymphoma | - | - |
AV7909 | Phase 3 | Anthrax | - | - |
PXVX0200 | Phase 3 | Cholera | - | - |
Raxibacumab | Phase 3 | Therapeutic Treatment of Inhalation Anthrax | - | - |
Gamunex | Phase 2 | Anthrax | - | - |
PXVX0200 10E9 | Phase 2 | Cholera | - | - |
of 1.7 x 10^10 CFU (Cohort 4) | Phase 2 | Typhoid | - | - |
1.1 x 10^10 CFU (Cohort 3) | Phase 2 | Typhoid | - | - |
5.0 x 10^9 CFU (Cohort 1) | Phase 2 | Typhoid | - | - |
7.5 x 10^9 CFU (Cohort 2) | Phase 2 | Typhoid | - | - |
FLU-IGIV | Phase 2 | Influenza A H3N2 | - | - |
Vaccinia virus: ACAM2000 smallpox vaccine | Phase 2 | Smallpox | - | - |
ACAM2000 Smallpox Vaccine | Phase 2 | Smallpox | - | - |
AIGIV | Phase 2 | Anthrax | - | - |
Ciprofloxacin | Phase 2 | Anthrax | - | - |
PXVX0200 10E8 | Phase 2 | Cholera | - | - |
Frequently asked questions
What is in Emergent BioSolutions Inc.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in Emergent BioSolutions Inc.'s (EBS) pipeline across Phase 3, Phase 2. Its lead program is ACAM2000 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Emergent BioSolutions Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Emergent BioSolutions Inc. (EBS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EBS biotech catalysts?→
Add EBS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Emergent BioSolutions Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.